Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases

Citation
Pj. Zhang et al., Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases, MOD PATHOL, 13(4), 2000, pp. 452-458
Citations number
21
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
MODERN PATHOLOGY
ISSN journal
08933952 → ACNP
Volume
13
Issue
4
Year of publication
2000
Pages
452 - 458
Database
ISI
SICI code
0893-3952(200004)13:4<452:IOM(IA>2.0.ZU;2-8
Abstract
MIC2 is characteristically expressed in lymphoblastic lesions and Ewing's/p rimitive neuroectodermal tumor sarcomas. Although MIC2 has recently been re ported in chloroma and rare terminal deoxynucleotidyl transferase-positive acute myelogenous leukemia (AML), the incidence and the significance of MIC 2 (CD99) immunoreactivity in myeloid lesions is not clear. In this study, w e evaluated MIC2 positivity in a variety of myeloid diseases and normal mar row to determine its incidence and distribution in myeloid diseases; its co rrelation with dow cytometric and cytogenetic data in AML; and its associat ion with leukemic transformation, relapse, and chloroma formation Paraffin sections of 11 chloromas and 94 bone marrow core biopsies from 66 patients were stained with CD99 monoclonal antibody 12E7. Of 94 bone marrow core bio psies, there were 30 AML, (fragment antigen binding M0 to M6), 23 remission s, 5 relapses, 12 myeloproliferative disorders, 13 myelodysplastic syndrome s, and 11 normal marrows from patients who did not have leukemia CD99 immun oreactivity was evaluated with light microscopy. MIC2 expression was seen i n leukemic blasts in 6 of 11 chloromas (55%) and 13 of 30 AML (43%) but rar ely in myeloproliferative disorders, myelodysplastic syndromes, remission, and normal marrow CD99 tended to be positive in M1-, M3-, and HLA-Dr-negati ve AML and negative in AML with relapse. MICE expression did not correlate with the karyotype independent of French-American-British Cooperative Group classification and the disease remission or occurrence of chloroma in AML. We concluded that MIC2 is commonly expressed in leukemic blasts of AML and is not predictive of leukemic transformation from myeloproliferative disor ders and myelodysplastic syndromes or chloroma formation. Caution should be taken when using MIC2 as a marker for Ewing's sarcoma/ primitive neuroecto dermal tumor or lymphoblastic lymphoma on paraffin sections of either soft tissue or bone marrow specimens.